IDH1 and neoplasm: Isoform-selective IDH inhibitors and peptide vaccines targeting IDH-mutant gliomas have shown translational potential in preclinical and clinical studies by interfering with both the cellular metabolism and the relative composition of target-specific tumor-infiltrating cytotoxic T cells [97,98].